Samumed said it has sold North American rights to its Phase I idiopathic pulmonary fibrosis (IPF) candidate SM04646 to United Therapeutics, in a deal that could generate more than $350 million for the privately-held San Diego biotech.
SUBSCRIBE
Biohealth Innovation
Founding Member of
